Clinical Trial Update: A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of BMS-986205 alone and with nivolumab in Chinese patients with advanced malignant solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Malignant Solid Tumors

Drugs mentioned

• BMS-986205 (BMS-986205)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-28